- Conditions
- Breast Cancer
- Interventions
- herceptin, adriamycin, cyclophosphamide, taxol
- Biological · Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2019
- U.S. locations
- 141
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 119 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 7,623
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF/VEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 25
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 18 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Interventions
- BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
- Biological · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- LY2422347, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 24 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Anaheim, California • Burbank, California + 19 more
- Conditions
- Ankle Fracture, Pilon Fracture
- Interventions
- ankle or distal tibia surgery
- Procedure
- Lead sponsor
- AO Clinical Investigation and Publishing Documentation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • New York, New York
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Ovarian Cancer
- Interventions
- Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Obicetrapib, Placebo
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 199
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, liraglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more
- Conditions
- Celiac Disease
- Interventions
- Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
- Drug · Dietary Supplement
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 58
- States / cities
- Anniston, Alabama • Homewood, Alabama • Mobile, Alabama + 50 more
- Conditions
- Visual Acuity
- Interventions
- senofilcon A prototype, Dailies Total 1
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 19
- States / cities
- San Francisco, California • Jacksonville, Florida • Longwood, Florida + 13 more
- Conditions
- Coronary Artery Disease
- Interventions
- adenosine, regadenoson
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • St Louis, Missouri
- Conditions
- Arthroplasty, Replacement, Hip
- Interventions
- Trident II Tritanium Acetabular Shell
- Device
- Lead sponsor
- Stryker Orthopaedics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Jacksonville, Florida • Des Plaines, Illinois + 5 more
- Conditions
- Deglutition Disorders, Esophageal Diseases, Eosinophilia
- Interventions
- assessment of disease activity using the EEsAI
- Other
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Other
- Eligibility
- Not listed
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • San Diego, California • Aurora, Colorado + 10 more
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- AXA1125, Placebo
- Drug
- Lead sponsor
- Axcella Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
- Conditions
- Pancreatic Cancer
- Interventions
- Proton radiation and chemotherapy
- Radiation
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Salmeterol 50mcg/ Fluticasone Propionate 500mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 190
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 105
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
- Conditions
- Renal Impairment
- Interventions
- Febuxostat, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 488
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Burbank, California + 295 more
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more